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Sarpogrelate hydrochloride reduced intimal
hyperplasia in experimental rabbit vein graft
Akio Kodama, MD,a Kimihiro Komori, MD, PhD,a Keisuke Hattori, MD, PhD,a
Dai Yamanouchi, MD, PhD,a Junko Kajikuri, PhD,b and Takeo Itoh, PhD,b Nagoya City, Japan
Objectives: The selective 5-HT2A receptor antagonist sarpogrelate has been clinically used for treatment in atherosclerotic
diseases. However, it remains unknown whether administration of sarpogrelate inhibits intimal hyperplasia seen in
autologous vein grafts. Therefore, we sought to clarify this question using an experimental rabbit vein graft model.
Methods:Male rabbits were divided into two groups: a control group and a sarpogrelate-treated group. The jugular vein
was interposed in the carotid artery in reversed fashion for 4 weeks and intimal hyperplasia of the grafted vein was
measured (n  8, in each group). Acetylcholine (ACh)-induced endothelium-dependent relaxation was tested by
precontraction with prostaglandin F2 (PGF2, 5 M) (n 5, in each). endothelial nitric oxide synthase (eNOS) protein
expression and superoxide production of these veins were also assessed.
Results: The suppression of intimal hyperplasia was significantly greater in the sarpogrelate-treated group than in the
control group. ACh induced an endothelium-dependent relaxation in the sarpogrelate-treated group (but not in the
control group). In endothelium-intact strips from the sarpogrelate-treated group, the nitric oxide (NO) synthase
inhibitor nitroarginine enhanced the PGF2-induced contraction and blocked the ACh-induced relaxation. Immunore-
active eNOS protein expression was similar between the two groups but superoxide production (estimated from ethidium
fluorescence) in endothelial cells was significantly smaller in the sarpogrelate-treated group.
Conclusion: The present results indicate that in vivo blockade of 5-HT2A receptors leads to an inhibition of intimal
hyperplasia in rabbit vein graft. It is suggested that an increased function of endothelium-derived NO through a
reduction in endothelial superoxide production may be a possible underlying mechanism for this. These novel findings
support the clinical usefulness of sarpogrelate for preventing intimal hyperplasia in vein graft after bypass grafting.
(J Vasc Surg 2009;49:1272-81.)
Clinical Relevance: Intimal hyperplasia is a major obstacle to patency after vein grafting. Despite a diverse array of trials
to prevent it, a satisfactory therapeutic strategy for clinical use has not been established. We report here the inhibitory
effect of 5-HT2A receptor antagonist, sarpogrelate hydrochloride on the development of vein graft intimal hyperplasia.
In addition, we demonstrate that sarpogrelate showed endothelium-dependent relaxation through a reduction in
endothelial superoxide production in vitro. Because the clinical benefits and safety of sarpogrelate have been established
to a certain extent through long-term clinical usage, the study provides further evidence to support the clinical
investigation of the role of sarpogrelate in prevention of intimal hyperplasia in venous bypass grafting.Despite the progress made in the area of endovascular
therapy, surgical revascularization using autologous veins
still remains the most widely practiced therapy for periph-
eral artery disease. However, approximately 30% of these
autologous vein grafts occlude within 5 years.1 Although
acute bypass failure is typically caused by problems in
surgical techniques and thrombosis, late graft failure devel-
ops as a result of intimal hyperplasia and subsequent accel-
erated atherogenesis.2,3 Hemodynamic factors such as a
low flow velocity and a low shear stress result in the increase
in intimal thickness.4,5 Several studies have demonstrated
the importance of preserving the function of endothelium-
derived nitric oxide (NO) in order to inhibit the develop-
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1272ment of intimal hyperplasia of autologous vein graft. We
previously demonstrated a close relationship between the
degree to which the function of NO in vein graft is pre-
served and the magnitude of intimal hyperplasia.6,7 It is
suggested that the extent of intimal hyperplasia of autolo-
gous vein graft can be significantly greater under poor-
runoff conditions than under normal conditions due to
increased endothelial dysfunction.5
Sarpogrelate is a novel, selective 5-HT2A receptor an-
tagonist and inhibits 5-HT-induced platelet aggregation
and vascular smooth muscle cell (VSMC) proliferation.8
This agent has been used clinically to prevent atheroscle-
rotic disease in Japan.9,10 It was found that chronic admin-
istration of sarpogrelate in vivo reduces intimal hyperplasia
in balloon-injured artery in hypercholesterolemic rabbits.11
However, little information is available concerning the
effect of administering sarpogrelate has on intimal hyper-
plasia of autologous vein grafts.
The present study was therefore undertaken to deter-
mine whether oral administration of sarpogrelate could
inhibit intimal hyperplasia in experimental vein graft in vivo
under poor-runoff conditions and, if so, to also determine
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sarpogrelate on ACh-induced endothelium-dependent
NO-mediate relaxation, endothelial-derived nitric oxide
synthase (eNOS) expression, and superoxide production in
rabbit vein grafts were compared to a control group.
METHODS
Animals and chemicals. Sarpogrelate hydrochloride
was obtained from Tanabe-Mitsubishi Wellpharma Co,
Ltd, Osaka, Japan. Male Japan white rabbits (Nippon SLC,
Hamamatsu, Japan), each weighing 2.5 to 3.0 kg, were
used in this study. The rabbits were housed individually at
25 3°Cwith free access to water. The animal experiments
were fully reviewed by the Committee of Ethics on Animal
Experiments of the Faculty of Medicine, Nagoya City Uni-
versity. The study was also in conformance with the publi-
cation Guiding Principles for the Care and Use of Labora-
tory Animals (publication No. NIH 80-23, revised 1985).
Drug administration. The rabbits were randomly di-
vided into a control group that fed on commercial rabbit
chow (CR3) (CLEA Japan Inc, Tokyo, Japan) and a sar-
pogrelate-treated group that received CR3 with 25 mg/kg
per day sarpogrelate (Oriental Yeast Co, Ltd, Tokyo, Ja-
pan), as previously reported.12 Sarpogrelate administration
was started on the day of the operation and continued until
the end of the experiment. All rabbits appeared to be
healthy throughout the course of the study. The rabbits
which had half or less of oral intake were omitted.
Vein graft implantation. Carotid interposition-
reversed jugular vein grafts were performed, as previously
described.13-15 Anesthesia was induced intramuscularly
with ketamine hydrochloride (50 mg/kg) and xylazine (10
mg/kg) and maintained with the intravenous (i.v.) admin-
istration of ketamine hydrochloride (10 mg/kg) and xyla-
zine (10 mg/kg).
After a longitudinal neck incision, the right jugular vein
and the right common carotid artery were exposed. The
branches of the jugular vein were carefully ligated with 8-0
polypropylene sutures and divided. An approximate 2.5-cm
segment of the jugular vein was taken for autologous
reversed-vein graft. Graft harvesting was completed with
meticulous care to avoid injuring the graft wall, and the
harvested graft was kept moistened in heparinized saline (5
IU/mL) at room temperature. The animals were systemi-
cally heparinized (200 IU/kg), and the internal carotid
artery and two of the three branches of the external carotid
artery were then ligated. The most inferior branch of the
external carotid artery served as the only outflow for the
poor-runoff conditions.13 The common carotid artery was
clamped distally and proximally, and a graft was anasto-
mosed in an end-to-end fashion into the divided artery with
interrupted 8-0 polypropylene sutures under a surgical
microscope. The wound was closed layer to layer.
Harvest of implanted grafts. At each time point after
implantation, the vein grafts were harvested under general
anesthesia as previously described.14 In brief, the graft was
isolated and harvested after systemic heparinization (200IU/kg i.v.) and the rabbit was then sacrificed by an over-
dose of pentobarbital (50 mg/kg i.v.). The harvested vein
graft was fixed with 4% formaldehyde at a pressure of 100
mm Hg for 30 minutes and the perfused vein graft was
immersed in the same fixative overnight at room tempera-
ture. A middle portion of the harvested graft was used for
histological study and immunohistochemistry. Each sample
was embedded in paraffin and cut into 5-m sections.
Assessment of intimal hyperplasia. Four weeks after
the operation, vein grafts were harvested and their intimal
hyperplasia was assessed as previously described.14 In brief,
four sections were obtained from each vein graft and each
section was stained with either hematoxylin and eosin or
the elastica van Gieson method. The intimal hyperplasia
was measured by MACSCOPE (Mitani Co, Fukui, Japan)
at eight randomly selected different views per section and
these were averaged. The four sections were examined in
the same way and the values were averaged to represent
intimal hyperplasia in the graft. The extent of intimal
hyperplasia was expressed as an intima/media index (intima
thickness divided by media thickness).
Immunohistochemical staining for proliferative
activity. Two weeks after implantation, vein grafts were
harvested. The formalin-fixed, paraffin-embedded tissue
sections were deparafinized in xylene/ethanol series. After
blocking the endogenous peroxidase activity with 3% hy-
drogen peroxide in methanol for 10 minutes at room
temperature, the specimens were preincubated with normal
horse serum for 30 minutes (to decrease nonspecific bind-
ing). After washing with phosphate-buffered saline (PBS)
solution, the sections were then incubated at room temper-
ature for 60 minutes with monoclonal antibodies directed
against proliferative cell nuclear antigen (PCNA) (clone PC
10, 1:200 dilution; DAKO Cytomation Inc, Carpinteria,
Calif). These sections were then treated with the DAKO
EnvisionSystem, following the manufacturer’s instructions
using 3,3=-diaminobenzidine (DAB) plus substrate-chromo-
gen. Each section was then lightly counterstained with hema-
toxylin, and brown-stained positive cells were counted.
To calculate the positive index (positive cells and total
cells) in the neointima region, eight high-power fields
(400) per section were randomly selected in a blinded
manner, and these were averaged to represent the number
of cells in that section. The cells were counted in such a way
into two sections and these were averaged to consider a
representative in one vein graft. The number of positive
nuclei divided by the total number of nuclei was defined as
the PCNA index in the neointima of the vein graft.13,14
Phenotypic alteration in smooth muscle cell (SMC)
in vein graft. To examine phenotypic alteration of
VSMCs in vein graft, myosin heavy chain isoforms were
immunostained using specific monoclonal antibodies
against human SM1 and SMemb (Yamasa Corp, Tokyo,
Japan) in paraffin-embedded sections of vein grafts at 2
weeks after implantation.16 After deparaffinization and re-
hydration, the sections were preincubated with 3% hydro-
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placed in a microwave oven for 5 minutes followed by a
20-minute cool down. They were then preincubated with
normal horse serum to reduce nonspecific reactions. After
washing with PBS, the sections were incubated with either
monoclonal antibody (diluted 1:100 in each case) at room
temperature for 60minutes. The sections were then treated
with DAKO Envision System, following the manufac-
turer’s instructions. Each section was counterstained
with hematoxylin, dehydrated, and mounted. To calcu-
late the positive index, eight high-power fields (400)
per section were randomly selected in a blinded manner
and the positive cell areas in the neointima were mea-
sured and averaged to represent the area in one section.
The areas were measured in two sections and these were
averaged to be representative for one vein graft. The
positive cell area divided by the neointima area was
defined as the SM1 and SMemb index.
ACh-induced endothelium-dependent relaxation.
The vein grafts at 4 weeks after implantation were immedi-
ately excised and placed in Krebs solution of the following
millimolar composition: Na 137.4; K 5.9; Mg2 1.2;
Ca2 2.5; HCO3
- 15.5; H2PO4
- 1.2; Cl- 134; glucose
11.5, and then cleaned by removing the connective tissues.
After each vein graft had been cut open along its long axis
using small scissors, circularly cut strips were carefully pre-
pared so as not to damage the endothelium. In some strips
the endothelium was carefully removed by gentle rubbing
of the internal surface of the vessel using small razor blades.
Circlarly cut strips (3.5 mm long, 1 mm wide) were
mounted horizontally in a small chamber and attached to a
strain gauge (AE801; SensoNor ASA, Horten, Norway),
allowing us to record isometric tension. The chamber with
a capacity of 0.3 mL was continuously perfused with Krebs
solution at a flow rate of 1.5 mL/minute. The transducer
was connected to a carrier amplifier (AS2101; NEC- San-ei
Instruments, Tokyo, Japan) and the output signal was fed
into a Macintosh computer (Apple Co, Tokyo, Japan)
through an analogue-digital converter (MacLab, AD In-
struments Pty Ltd, Castle Hill, Australia). Drift was less
than 3 N per hour. The resting tension was adjusted to
obtain the maximum contraction in high K solution (128
mM). Each preparation was allowed to equilibrate for 1
hour before the start of the experiment.
Endothelium-dependent relaxation was induced by an
application of acetylcholine (ACh, 1 M, Sigma Chemical
Co, St Louis, Mo) during the contraction induced by
prostaglandin F2 (PGF2, 5 M,Ono Pharmaceutical Co,
Ltd, Osaka, Japan). For this set of experiments, the prepa-
rations were first contracted with PGF2 and then, after a
steady-state contraction had been attained, ACh was ap-
plied. In order to examine the effect of the NO synthase
inhibitor NG-nitro-L-arginine (L-NNA) on ACh-induced
relaxation, the endothelium-intact strips were pretreated
with L-NNA for 60 minutes and then the effects of ACh (1
M) were examined in the presence of PGF2  L-NNA.
In some strips from the sarpogrelate group, the endothe-lium was removed to examine whether the ACh-induced
relaxation was endothelium-dependent or not.7,17
Immunohistochemical staining for eNOS. A mid-
dle part of the vein graft at 4 weeks after implantation was
embedded in OCT compound (Tissue Tek; SAKURA Fi-
netechnical, Tokyo, Japan) and frozen at80°C. Cryosec-
tions were cut at 4 m thickness on a cryostat (Microtome
Cryostat HM 550; MICROM International GmbH, Wall-
dorf, Germany), then mounted on Matsunami adhesive
silane (MAS)-coated glass slides (Matsunami Glass, Kishi-
wada, Japan) for immunohistochemistry. After a washout
with PBS, the sections were incubated at 4°C overnight with
rabbit anti-bovine eNOS serum (1:100 dilution; Affinity Bio
Reagents, Golden, Colo) as the primary antibody. After the
sections had been rinsed with PBS, they were incubated with
the secondary antibody (Alexa Fluor 488 goat anti-rabbit IgG
antibody; dilution 1:5000; Molecular Probes, Eugene, Ore)
for 1 hour at room temperature. After a further washing with
PBS, the fluorescence of Alexa Fluor 488 was detected by
confocal-laser-scanning microscopy (LSM5 PASCAL; Carl
Zeiss, Jena, Germany). The acquisition of images from differ-
ent groups of rabbits was performed under identical condi-
tions. Fluorescent 12-bit images were acquired and then ana-
lyzed using commercial software (LSM5 PASCAL), as
previously reported.18 The total fluorescence intensities ob-
tained from the four areas (36  36 pixels square) in each
preparation were averaged, and this (ie, one value for each
preparation) was used for subsequent analysis.
Superoxide production. Dihydroethidium (Molecu-
lar Probes, Eugene, Ore), an oxidative fluorescence dye was
used to detect superoxide-anion production in vein grafts
at 4 weeks after implantation. Segments (3.5 mm long) of
vein graft were incubated in Krebs solution at 37°C for 2
hours andwere then frozen inOTC compound. The frozen
vein graft was cut transversely (10 m thickness) on a
cryostat (Microtome Cryostat HM 550; MICROM Inter-
national GmbH, Walldorf, Germany). The sections were
placed on MAS-coated glass slides and incubated in PBS
solution containing 2 Mdihydroethidium in the presence
or absence of 0.1 mM N-nitro-L-arginine methyl-ester
(L-NAME, to study possible sources of superoxide produc-
tion) at 37°C for 30 minutes under a light-protected con-
dition. Images were obtained by confocal-laser-scanning
microscopy (LSM5 PASCAL; Carl Zeiss, Jena, Germany)
using an excitation wavelength of 488 nM and emission
fluorescence through a 585 nM-long pass filter. Identical
conditions were used to acquire images (12-bit) that were
subsequently analyzed using commercial software (LSM5
PASCAL).18,19 The total fluorescence intensities obtained
from the four areas (36  36 pixels square) in each prepa-
ration were averaged, and this (ie, one value for each
preparation) was used for subsequent analysis.
Statistical analysis. All values are expressed as mean
standard error of the mean (SEM). Stat View 5.0 (SAS
Institute) software was used for statistical calculations.
Paired or unpaired t test with an F test was used for statistical
analysis. Differences between groups were considered to be
statistically significant when the P value was .05.
group
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All animals survived and all vein grafts were patent until
the time of harvest.
Effect of sarpogrelate-treatment in intimal hyper-
plasia and cell proliferative activity in vein graft.
Intimal hyperplasia developed in both groups (n  5 in
each group), but the level of the intimal thickness was signif-
icantly smaller in the sarpogrelate-treated group (52.0 10.3
m) than in the control group (161.3  37.7 m; P 
.05). The intima/media index was also significantly smaller
in the sarpogrelate-treated group (0.27 0.05) than in the
control group (0.59  0.12; P  .05; Fig 1).
The PCNA index in the neointima lesion was measured
in vein grafts harvested at 2 weeks after implantation, and it
was significantly smaller in the sarpogrelate-treated group
(24.9 0.9%) than in the control group (32.5 1.3%; P
.05; n  8 in each group; Fig 2).
Effect of sarpogrelate-treatment on expression of sub-
types of smooth muscle cell. Most cells located in the
neointima of the vein grafts harvested at 2 weeks after
implantation were positive for SM1 in both the groups
(control group, n  8, 86.7  2.5%; sarpogrelate-treated
group, n  8, 90.1  1.4%; Fig 3, A). SMemb-index was
significantly smaller in the sarpogrelate-treated group (50.4
4.6%) than in the control group (84.4  4.3%; P  .05:
Fig 1. Effect of sarpogrelate on development of inti
operation. A, Microscopic findings in the middle portio
sarpogrelate-treated group (right panel). Arrowheads in
B, Quantitative analysis of the intimal hyperplasia of vein
sarpogrelate-treated group (n  5) than the control gro
smaller in the sarpogrelate-treated group (n  5) than in
standard error of the mean (SEM), *P  .05 vs controlFig 3, B).Effect of sarpogrelate-treatment on PGF2-induced
contraction and ACh-induced relaxation. In vein grafts
harvested at 4 weeks after implantation, PGF2 (5 M)
induced a contraction in the endothelium-intact strips from
both the groups (Fig 4). The NO synthase inhibitor L-
NNA significantly enhanced the PGF2-induced contrac-
tion in endothelium-intact strips from the sarpogrelate-
treated group (n  5; P  .05), but not those from the
control group (n  5; P  .11). This effect of L-NNA was
not observed in endothelium-denuded strips from the sar-
pogrelate-treated group (n  4; P  .20).
During the contraction induced by PGF2, ACh (1 M)
induced a relaxation in endothelium-intact strips from the
sarpogrelate-treated group (n  5; P  .05), but not those
from the control group (n  5; P .45) (Fig 5). The ACh-
induced relaxation was not observed in endothelium-
denuded strips from the sarpogrelate-treated group (n  4).
L-NNA blocked the ACh-induced relaxation in endothelium-
intact strips from the sarpogrelate-treated group (n5) (Fig 5).
Effect of sarpogrelate-treatment on eNOS protein ex-
pression and superoxide production. Immunoreactive flu-
orescence against eNOS protein was detected only in the
endothelial layer of vein graft harvested at 4 weeks after
implantation (Fig 6,A), and there was no significant differ-
ence in these intensities between the two groups (n  4 in
yperplasia in autologous vein grafts at 4 weeks after
vein graft from the control group (left panel) and the
the internal elastic lamina (elastic van Gieson staining).
ts. The intimal thickness was significantly smaller in the
 5). C, The intima/media index was also significantly
control group (n  5). Results are expressed as mean 
.mal h
n of a
dicate
graf
up (n
theeach group; P  .82; Fig 6, B).
the
trol g
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rescence intensities) was found in both the endothelial and
the medial region in the vascular wall of vein grafts from
both the groups (n  4 in each group). Fluorescence
intensity in the endothelial region was significantly smaller
in the sarpogrelate-treated group than in the control rab-
bits (P  .05), while there was no significant difference in
Fig 2. Effects of sarpogrelate on proliferative activity i
antigen (PCNA) index was measured in vein grafts at 2 w
haematoxylin.A,Microscopic findings with PCNA staini
(left panel) and the sarpogrelate-treated group (righ
neointima (original magnification400).B,Quantitativ
index (the number of PCNA-positive cells divided by t
arpogrelate-treated group (n  8) compared with that in
standard error of the mean (SEM), *P  .05 vs the conthe medial region between the two groups (P .22) (Fig 7).L-NAME (0.1 mM) inhibited the superoxide production
only in the endothelial region of vein grafts in both the
groups (P  .01 vs in the absence of L-NAME) (Fig 7).
DISCUSSION
Sarpogrelate, a 5-HT2Areceptor antagonist, has been
used clinically as an anti-platelet drug for prevention of
intima of autologous vein grafts. The proliferative cell
fter implantation. Counterstaining was done lightly with
the middle portion of a vein graft from the control group
el). Arrowheads indicate PCNA-positive cells in the
ysis of the frequency of PCNA-positive cells. The PCNA
mber of total cells) was significantly suppressed in the
control group (n  8). Results are expressed as mean 
roup.n neo
eeks a
ng in
t pan
e anal
he nuthrombosis in atherosclerotic disease such as arteriosclero-
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sarpogrelate improves endothelial function in balloon-
injured porcine coronary artery20 and aorta in cholesterol-
fed rabbits,12 suggesting that chronic administration of
sarpogrelate may reduce intimal hyperplasia in autologous
vein grafts. However, little information is so far available on
this effect of sarpogrelate. Here, we have demonstrated that
chronic in vivo administration of sarpogrelate indeed inhibits
intimal hyperplasia and proliferative activity in the neointima
of vein grafts from rabbits. We also found that this treatment
enhanced ACh-induced, endothelium-dependent NO-me-
diated relaxation in the vein grafts. To our knowledge, this
is the first study to report the beneficial effects of the
chronic administration of the 5-HT2A receptor antagonist
on endothelium-dependent relaxation and intimal hyper-
plasia in vein grafts.
Intimal thickening of autologous vein grafts is the
major cause of late graft failure.2,3 Implantation of the vein
graft in arterial circulation induces various changes (such as
increased sheer stress, loss of endothelial cells, migration
and invasion of inflammatory cells, and migration and
proliferation of VSMCs),21,22 thus, leading to intimal hy-
perplasia. Several reports described the phenotypic charac-
teristics of VSMCs in experimental animals using the anti-
bodies against myosin heavy chain (MHC) isoforms.16,23
SM1 is a constitutively expressed isoform from fetal to adult
Fig 3. Immunohistochemistry using antibodies against
A, Most cells in the neointima were positive for monoclon
the control and the sarpogrelate-treated group (n  8 in
sarpogrelate-treated group (n  8) than in the control g
of the mean (SEM), *P  .05 vs the control group.SM1 (A), SMemb (B) in neointima of autologous vein grafts.
al antibody against SM1, and SM1 index was similar between
each case). B, SMemb index was significantly smaller in the
roup (n  8). Results are expressed as mean  standard errorlife. SMemb (a nonmuscle MHC isoform) is expressed inFig 4. Effects of sarpogrelate on prostaglandin F (PGF)2á-
induced contraction in autologous vein grafts. PGF2á (5 ìM)
induced a contraction in both control and sarpogrelate-treated
group. In the sarpogrelate-treated group, L-NNA significantly
enhanced the PGF2á-induced contraction in endothelium-intact
strips, but not in endothelium-denuded strips. Such an effect of
L-NNA was not observed in endothelium-intact strips from the
control group. E(), endothelium-intact strips; E(), endotheli-
um-denuded strips; L-NNA(), in the absence of L-NNA; L-
NNA(), in the presence of L-NNA. Results are expressed as
mean  standard error of the mean (SEM), *P  .05 vs L-
NNA().
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is down-regulated in adults. SMemb is also expressed in
phenotypically-modulated, dedifferentiated VSMCs. It was
suggested that intimal VSMCs in rabbit vein grafts at 2
weeks after transplantation appeared to be proliferating as
determined by means of PCNA immunostaining and
retained the dedifferentiated phenotype.23,24 Consistent
with these findings, in our rabbit vein grafts at 2 weeks after
transplantation, a high amount of SMemb expression was
identified in the intimal. Sarpogrelate has been used clini-
cally for atherosclerotic patients as an antiplatelet agent.
More importantly, we found that chronic administration
Fig 5. Effects of sarpogrelate on acetylcholine (AC
A, Actual tracings of the effects of ACh in endothelium-in
(left panel) and presence of L-NNA (right panel). A
prostaglandin F (PGF)2á (5 ìM). B, Summary of the effe
amplitude of tonic contraction induced by PGF2 befor
1.0 for each strip. In sarpogrelate-treated group, ACh in
endothelium-denuded strips. In endothelium-intact str
PGF2-induced contraction and blocked the ACh-in
L-NNA(), in the presence of L-NNA. Results are expr
vs before application of ACh, ††P  .01 vs L-NNA().of sarpogrelate reduced (1) the proliferative activity (es-timated from PCNA immunostaining), (2) intimal thick-
ness and (3) dedifferentiated VSMCs (estimated from
SMemb expression), suggesting that sarpogrelate inhi-
bits the development of vein graft intimal hyperplasia
in vivo.
Various treatments have been examined to reduce inti-
mal hyperplasia of vein grafts,13,14,22 but a standard clinical
treatment has not yet been established. Some relationship
between graft failure and the loss of endothelium-depen-
dent relaxation has been suggested in reversed vein grafts.6
For example, we previously demonstrated that pronounced
intimal thickening and increase in cell proliferative activity
duced mechanical response in autologous vein grafts.
strips from the sarpogrelate-treated group in the absence
1 ìM) were applied during a contraction induced by
sarpogrelate on ACh-induced mechanical response. The
lication of ACh was normalized as the relative tension of
a relaxation in the endothelium-intact strips but not in
the sarpogrelate-treated group, L-NNA increased the
relaxation. L-NNA(), in the absence of L-NNA;
as mean standard error of the mean (SEM), *P .05h)-in
tact
Ch (
ct of
e app
duced
ips of
duced
essedin the neointima of experimental autologous vein grafts is
rom
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NO-mediated relaxation.6,25 It was found that intimal hy-
perplasia of vein grafts was suppressed by an increase in NO
production through gene transfer of eNOS26 or oral ad-
ministration of the NO precursor L-arginine.7 NOmay also
modulate VSMC mitogenesis and proliferation.27 In the
present experiments, using vein grafts at 4 weeks after
transplantation, we found that (1) ACh-induced relaxation
in the sarpogrelate-treated group but not in the control
group and (2) the ACh-induced relaxation was abolished
when the endothelium was removed or the NO synthase
inhibitor L-NNA was present. These results for the first time
indicate that chronic administered sarpogrelate enhances
ACh-induced, endothelium-dependent NO-mediated relax-
ation in experimental autologous vein grafts.
At least two possible mechanisms have been so far consid-
ered to account for the enhancement of endothelium-de-
rived NO function by sarpogrelate-treatment: (1) increase
in NO production in endothelial cells and/or (2) decrease
in the production superoxide (that breaks down NO to
peroxynitrite). It was found that sarpogrelate enhances
eNOS expression and, thus, increases NO production in
Fig 6. Effects of sarpogrelate on expression of eNOS
against eNOS protein can be identified only in the endot
sarpogrelate on eNOS protein expression. There was no d
two groups. Mean of data from four different sections (faorta of hypercholesterolemic rabbits,12 while it was foundthat sarpogrelate reduces superoxide production in neutro-
phils in vitro.28 In the present experiments, we found that
(1) the expression level of eNOS protein (that expressed
only in endothelial cells) was similar between the sarpogre-
late-treated group and the control group but (2) superox-
ide production in the endothelial region (but not in the
medial region) was much smaller in the sarpogrelate-
treated group than in the control group. Superoxide is
thought to generate peroxynitrite by reaction with NO,
which oxidizes tetrahydrobiopterin (BH4), leading to
“eNOS uncoupling”. Once “eNOS uncoupling” has been
developed, eNOS becomes dysfunctional and produces
superoxide rather than NO.18,29,30 We found that L-
NAME (an inhibitor of eNOS-dependent superoxide pro-
duction)29 attenuated superoxide production in the endo-
thelial region (but not the medial region) of vein grafts,
suggesting that “eNOS uncoupling” may have developed
in our experimental autologous vein grafts. We demon-
strated before that celiprolol, 	-adrenoceptor antagonist
inhibited the superoxide production in endothelial cells.31
However, for the first time the results in this experiment
suggest that not only does chronic administration of
ein in autologous vein grafts. A, Immunofluorescence
l region in both the groups. B, Summary of the effect of
nce in the levels of eNOS protein expression between the
four animals) with standard error of the mean (SEM).prot
helia
ifferesarpogrelate inhibit superoxide production in endothe-
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leading to an increase in the endothelium-derived NO
Fig 7. Effects of sarpogrelate on superoxide productio
(estimated from ethidium fluorescence) can be seen in bo
presence of L-NAME; L-NAME(): in the absence o
superoxide production. Superoxide production in the e
treated group than in the control group. L-NAME sig
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mean (SEM), **P  .01 vs in the absence of L-NAME,function. However, further studies (such as an investiga-tion of the effect of sarpogrelate in L-NAME-treated
animals) are required to definitively determine whether
sarpogrelate works though an NOS dependent or inde-
vascular wall of vein grafts. A, Superoxide production
endothelial and the medial region. L-NAME(): in the
AME. B, Summary of the effect of sarpogrelate on
elial region is significantly smaller in the sarpogrelate-
ntly inhibits fluorescence intensities in the endothelial
sections (from four animals) with standard error of the
.05 vs control.n in
th the
f L-N
ndoth
nifica
rentpendent mechanism.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 5 Kodama et al 1281CONCLUSION
Our present study clearly demonstrates that chronic
administration of sarpogrelate induces suppression of inti-
mal hyperplasia development in experimental autologous
vein grafts, possibly due to an inhibition of smooth muscle
cell proliferative activity and enhancement of endothelium-
derived NO function. This novel finding may facilitate the
clinical use of sarpogrelate hydrochloride in postoperative
patients to prevent late graft failure after bypass grafting.
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